Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03691974 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

A Phase 2 study of Osteoarthritis, Knee and Osteoarthritis, Hip, sponsored by Regeneron Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
180
Enrollment target
20
Study locations

NCT03691974 is a Phase 2 study of Osteoarthritis, Knee and Osteoarthritis, Hip that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 180 participants, below the 578-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03691974, a Phase 2 study of Osteoarthritis, Knee and Osteoarthritis, Hip, has completed, sponsored by Regeneron Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of the study is to evaluate the effect of fasinumab compared to placebo on peripheral nerves in participants with pain due to Osteoarthritis (OA) of the hip or knee. The secondary objectives of the study are to: * Evaluate the efficacy of fasinumab compared to placebo in participants with pain due to OA of the hip or knee * Evaluate the safety and tolerability of fasinumab compared to placebo in participants with pain due to OA of the hip or knee * Characterize the concentrations of fasinumab in serum in participants with pain due to OA of the hip or knee * Evaluate the immunogenicity of fasinumab in participants with pain due to OA of the hip or knee.

Conditions Studied

Osteoarthritis, Knee Osteoarthritis, Hip

Interventions

  • OTHER Placebo
  • DRUG Fasinumab

Study Locations (20)

Florida

  • Regeneron Study Site - Clearwater
  • Regeneron Study Site - Jacksonville
  • Regeneron Study Site - Miami
  • Regeneron Study Site - Ocoee
  • Regeneron Study Site - Orlando

Arizona

  • Regeneron Study Site - Glendale
  • Regeneron Study Site - Glendale
  • Regeneron Study Site - Phoenix
  • Regeneron Study Site - Tucson

Texas

  • Regeneron Study Site - Bellaire
  • Regeneron Study Site - Houston
  • Regeneron Study Site - Houston

Illinois

  • Regeneron Study Site - Chicago
  • Regeneron Study Site - Chicago

Ohio

  • Regeneron Study Site - Cincinnati
  • Regeneron Study Site - Columbus

California

  • Regeneron Study Site - Anaheim

Georgia

  • Regeneron Study Site - Woodstock

Michigan

  • Regeneron Study Site - Caro

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2018-10-15
Est. Completion 2021-01-07
Phase Phase 2

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03691974

The ClinicalTrials.gov registry entry for NCT03691974 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 578-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (69% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03691974 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Arizona, Texas.

Frequently Asked Questions

What is clinical trial NCT03691974 about?

NCT03691974 is a clinical study titled "Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee". The primary objective of the study is to evaluate the effect of fasinumab compared to placebo on peripheral nerves in participants with pain due to Osteoarthritis (OA) of the hip or knee. The secondary objectives of the study are to: * Evaluate the efficacy of fasinumab compared to placebo in part...

What is the current status of trial NCT03691974?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2018-10-15. Estimated completion is 2021-01-07.

What conditions does trial NCT03691974 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee, Osteoarthritis, Hip.

What interventions are being tested in trial NCT03691974?

The interventions under investigation include: Placebo (OTHER), Fasinumab (DRUG).

Who is sponsoring clinical trial NCT03691974?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03691974 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteoarthritis, Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Osteoarthritis, Knee

All registered trials for this condition

Osteoarthritis, Hip

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.